BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD

Published on :

BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the two companies have entered into a purchase agreement for BioNTech to acquire Kite’s solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, MD. The acquired Gaithersburg facility will provide production capacity to support clinical trials in the United States and will complement BioNTech’s existing cell therapy manufacturing facility in Idar-Oberstein, Germany. The facility will support the development of BioNTech’s expanding pipeline of novel cell therapies, including cancer product candidates based on its CAR-T Cell amplifying mRNA vaccine (CARVac) and NEOSTIM platforms as well as the newly acquired individualized neoantigen TCR program.

Q&A with Jaime Rodriguez-Canales, M.D., FEBP – The importance of Multiplex Immunofluorescence in the field of Immune-Oncology

Published on :

Q&A with Jaime Rodriguez-Canales, M.D., FEBP Dr. Rodriguez-Canales is a Senior Pathologist at MedImmune, and Course Director for the recent Multiplex Immunofluorescence in Immune-Oncology Symposium, a Bio-Trac program cosponsored by [….]

Abhita Batra, Otomagnetics CEO, Aims to Change the Lives of Childhood Cancer Survivors with Magnetic Drug Delivery Technology

Published on :

Abhita Batra, Otomagnetics CEO, Aims to Change the Lives of Childhood Cancer Survivors with Magnetic Drug Delivery Technology October 8, 2018 Abhita Batra, CEO Otomagnetics, Inc., is leading the growth [….]

Q&A with Immunomic’s Teri Heiland, PhD: What the ‘UNITE’ Technology Platform Could Mean for the Future of Immunotherapy

Published on :

Q&A with Immunomic’s Teri Heiland, PhD What the ‘UNITE’ Technology Platform Could Mean for the Future of Immunotherapy September 25, 2018   Teri Heiland, Ph.D. is the Senior Vice President [….]

Dr. Carol Nacy, CEO of Sequella, Takes on the Global Crisis of Anti-Microbial Resistance

Carol Nacy, Ph.D.
Published on :

Dr. Carol Nacy, CEO of Sequella, Takes on the Global Crisis of Anti-Microbial Resistance  For Dr. Carol Nacy, co-founder and CEO of Rockville, Maryland’s clinical-stage antibiotics developer Sequella, it all [….]